The 4th Human Abuse Liability & Abuse-Deterrent Formulations conference will be the largest and most specifically focused event in the world devoted entirely to designing, testing and marketing prescription drugs with a lowered risk of abuse. If you are interested in sponsorship or exhibition opportunities, please contact Eric Morrin, Senior Business Development Manager, at 212-400-6228 or email@example.com.
Alcami is a world-class supplier of comprehensive pharmaceutical development and manufacturing services headquartered in Wilmington, NC. We provide flexible, transparent and innovative services to small and mid-size pharma and biotech companies by offering individualized and integrated services across Active Pharmaceutical Ingredients (APIs), Drug Product, Development Services, and Analytical Testing. We strive to be the most customer-focused and reliable partner built on safety, compliance, strong scientific expertise and leading technologies.
Altasciences Clinical Research
Altasciences Clinical Research encompasses Algorithme Pharma and Vince & Associates Clinical Research, making it one of the largest early phase clinical CROs in North America. With more than 25 years of experience, Altasciences provides clinical development services to biopharmaceutical companies worldwide, including study conduct, medical writing, biostatistics, data management and bioanalysis.
DRUGSCAN©’s CAT.one™ laboratory-based manipulation and extraction studies are designed and conducted to produce data that can predict a product’s strengths and weaknesses to physical and chemical manipulations as well as support abuse-deterrent label claims. Employing state of the art technology and abuse-deterrent testing expertise, DRUGSCAN© has been at the forefront of designing and conducting manipulation and extraction studies for many of the leading abuse-deterrent product developers in the US and around the world.
Hassman Research Institute
HRI conducts a full complement of inpatient and outpatient Phase I-IV research trials, specializing in Psychiatry, Addiction, Pain Management, Human Abuse Liability, Hepatic/Renal, and Internal Medicine Therapeutic Areas. A highly experienced team of Board Certified Investigators, Psychometric and Pain/Addiction Raters, Clinical Research Coordinators, and Quality Assurance and Regulatory Affairs Specialists are the backbone of our infrastructure empowering HRI to meet critical project timelines while maintaining the highest standard of quality.
INC Research/inVentiv Health
INC Research/inVentiv Health (Nasdaq:INCR) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to address new market realities where clinical and commercial share expertise, data and insights to accelerate biopharmaceutical performance. With more than 22,000 employees and the ability to support customers in more than 110 countries, our global scale and deep therapeutic alignment enables INC Research/inVentiv Health to help customers successfully navigate an increasingly complex environment. For more information on our Raleigh, N.C.-based company, visit incresearch.com or inventivhealth.com.
Inflexxion combines substance abuse, behavioral health and pain management data with scientific methodology to provide solutions for regulatory reporting and informed decision-making. We collect, analyze and disseminate data for the purpose of risk and outcome management and quality improvement. Results are used by healthcare organizations and regulatory authorities to improve care, inform public policy and identify public health trends. To learn more, visit www.Inflexxion.com.
PRA Health Sciences
PRA Health Sciences’ early phase professionals live and breathe clinical pharmacology. As the most comprehensive high-end Phase I CRO in the world, PRA Early Development Services provide the unique scientific environment required for complex compound development in both healthy volunteers and special patient populations. Committed to the highest standards of clinical excellence and scientific expertise, we operate state-of-the-art facilities in The Netherlands and North America as well as an innovative patient pharmacology model in Central and Eastern Europe. Our fully harmonized, GLP-compliant laboratories are located close to our clinical units, enabling us to quickly analyze time-critical samples.
The RADARS® System collects timely product- and geographically specific prescription drug abuse, misuse and diversion data utilizing a mosaic strategy across all phases of the drug abuse pathway and provides these data to the pharmaceutical industry, regulatory agencies, policymakers and medical/public health officials. Additional RADARS® System services include postmarket surveillance, epidemiological studies, publication strategy, advisory committee consultation and advisory board participation. The RADARS® System is a governmental nonprofit operation of Denver Health and Hospital Authority.
The Grünenthal Group: International, Successful, Innovative
The Grünenthal Group is an independent, research-based pharmaceutical company headquartered in Germany. Grünenthal is present in 32 countries with 5,300 employees worldwide. In 2014 revenues were approximately $1.25 billion. Since 2010, Grünenthal has marketed its proprietary abuse-deterrent technology INTAC®, which restricts manipulation and impedes abuse due to high mechanical stability.